

A single mutation leads to a novel CNTF-analogue that is unable to interact with the IL-6 receptor. The CNTFR-specific analogue is a choice candidate to be used in the therapy of a number of neurodegenerative diseases and/or to regulate body weight without IL-6R-related side-effects.
Further Information: PDF
Patent- und Verwertungsagentur für die Wissenschaftlichen Einrichtungen in Schleswig-Holstein GmbH (PVA SH)
Phone: +49 (0)431/8009937
Contact
Dr. Alexandra Baumgartner